Molecular Partners AG
(NASDAQ: MOLN)
|
5:30 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $6.62 | Change: -0.38 | %Change: -5.43% | Volume: 6,789 |
Open: | $ 6.58 | Volume: | 6,789 | |
---|---|---|---|---|
High: | $ 6.99 | Yield(%) | 0.00 | |
Low: | $ 6.46 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 232.27M | |
EPS ($) | -2.01 | Shares Out: | 33.18M |
% Price Change (last 4 weeks): | 80.18 |
---|---|
% Price Change (last 13 weeks): | 79.49 |
% Price Change (last 26 weeks): | 67.87 |
% Price Change (last 52 weeks): | 14.85 |
% Price Change (year to date): | 67.47 |
Return on Equity (%): | -29.74 |
---|---|
Return on Assets (%): | -26.57 |
Return on Invested Capital (%): | -28.17 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | -880.70 |
Operating Profit Margin (%): | -868.26 |
|
|
50-day Moving Average: | $4.50 |
---|---|
200-day Moving Average: | $3.76 |
Avg. Daily Vol. (last 50 days): | 32,024 |
Avg. Daily Vol. (last 200 days): | 13,923 |
52-wk high: | $12.70 |
52-wk low: | $3.32 |
Bid: | $6.65 |
Ask: | $10.53 |
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
|
Molecular Partners AG
Wagistrasse 14 Schlieren ZH 8952 Phone: 41.44.755.77.00 Fax: 41.44.755.77.07 http://www.molecularpartners.com |
Earnings (1year) ($): | -2.01 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 6.38 |
Cash Flow ($): | -2.02 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 17.49 |
Price/Book (x): | 0.66 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 13.35 |
---|---|
Current Ratio (x): | 13.35 |
LT Debt/Equity (x): | 1.39 |
Total Debt/Equity (x): | 2.07 |